PPARA gene and phenprocoumon
| Autor: | Mariana R. Botton, Eliane Bandinelli, Tiago L. L. Leiria, Mara H. Hutz, Luis Eduardo Paim Rohde |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Genotype medicine.drug_class Polymorphism Single Nucleotide Biomarkers Pharmacological Phenprocoumon Gene Frequency Thromboembolism Internal medicine Genetics medicine Humans PPAR alpha PPARA Gene General Pharmacology Toxicology and Pharmaceutics Allele Molecular Biology Genotyping Genetics (clinical) Aged Aged 80 and over Dose-Response Relationship Drug CYP3A4 business.industry Anticoagulant Haplotype Anticoagulants Middle Aged Endocrinology Molecular Medicine Female business medicine.drug |
| Zdroj: | Pharmacogenetics and Genomics. 25:93-95 |
| ISSN: | 1744-6872 |
| Popis: | Phenprocoumon is an anticoagulant used for thromboembolic disorder prophylaxis metabolized mainly by CYP3A4. However, polymorphisms in this gene did not explain the observed variability. PPARA (peroxisome proliferator-activated receptor-α) is a nuclear receptor that, among others, influences CYP3A4 gene expression. The aim of this study was to determine whether PPARA gene polymorphisms and the CYP3A4*22 allele are associated with phenprocoumon dose variability. A total of 198 patients on a stable dose of phenprocoumon were included in the study. Genotyping was performed by allele discrimination using standardized TaqMan assays. Differences between the average phenprocoumon dose and genotypes/haplotypes were assessed by analysis of variance and multiple linear regression analyses. Patients with the PPARA rs4253728A allele needed higher phenprocoumon doses. However, the effect size (3%) of this association was small. The CYP3A4*22 allele was not associated with the dose of phenprocoumon. As this is the first report of an association between PPARA gene polymorphisms and phenprocoumon dose, future studies are warranted to confirm these results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|